IC PHARMA DISTRIBUTION
ActiveSummary
IC PHARMA DISTRIBUTION has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€346,912) and a net result of -€460. Equity is shrinking by about 3.1% per year across the filed financial years. Its solvency ranks better than 5% of 322 sector peers (NACE 58, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
20-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
25-08
NBB filing
Annual accounts filed
financial year 2024 · full format · 25 days late
2024
31-12
Financial
Back to profitnet €33,542
Net result €33,542 after one loss-making year.
04-07
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
19-07
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
31-12
Financial
Back to profitnet €344,696
Net result €344,696 after 4 loss-making years.
30-08
NBB filing
Annual accounts filed
financial year 2021 · full format · 30 days late
2021
27-10
NBB filing
Annual accounts filed
financial year 2020 · full format · 88 days late
2020
31-12
Financial
Weakest financial yearnet -€258,850
Net result drops to -€258,850, the lowest in the series; recovery starts the following year.
20-10
NBB filing
Annual accounts filed
financial year 2019 · full format · 81 days late
2019
30-08
NBB filing
Annual accounts filed
financial year 2018 · full format · 30 days late
2018
29-08
NBB filing
Annual accounts filed
financial year 2017 · full format · 29 days late
2017
25-07
NBB filing
Annual accounts filed
financial year 2016 · full format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
0 of 6 deeds read
About the unread acts
We know of 6 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.